Supergen, Inc

Ashok Y Gore

Sanjeev Redkar

Joseph Rubinfeld

Rajashree Joshi-Hangal

Rajesh Shrotriya

Stephanie Gong

Xichen Zhang

Rajashree Joshi

Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.

Kit for delivering decitabine in vivo

Method of administering decitabine

A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6&#xb0; C., and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts.

Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor

A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9&#xb0; C., and an exotherm at between 279.3 and 281.3&#xb0; C.

Liquid formulation of decitabine and use of the same

A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having an IR spectrum with an absorption centered between 3625 cm and 3675 cm and containing more than a trace of water.

Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof

A method is provided for preparing a pharmaceutical composition comprising: taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen for a period of time, the exposure to the gas over the period of time causing an acidity of the polyoxyethylated castor oil to increase; and forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil and a pharmaceutically active agent such as paclitaxel; wherein at least 80% of the potency of the pharmaceutically active agent is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40&deg; C.

Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions

Amorphous forms of 9-nitrocamptothecin are provided by grinding or pulverizing different polymorphic forms of 9-nitrocamptothecin, and the polymorphic forms are characterizable as having an X-ray powder diffraction pattern with discernable diffraction lines at different &deg;2&thgr; values for Cu K&agr; radiation having a wavelength of 1.5406 Angstrom.

Paclitaxel formulation

A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 175.5 and 177.5&deg; C., an exotherm at between 181.7 and 183.7&deg; C., and an IR spectrum with no absorption centered between 3625 cm and 3675 cm .

A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 149.2 and 151.2&deg; C., an exotherm at between 162.6 and 164.6&deg; C., and an exotherm at between 272 and 274&deg; C.

Oral formulation for paclitaxel

A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharmaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structures

Formulation for paclitaxel

Disclosed are compositions comprising paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent, together with kits comprising the composition and methods of using the composition.

Growing community of inventors

San Ramon, CA, United States of America

Ashok Y Gore